DPV-001 Vaccine Containing Cancer’s “Dark Matter” Yields 2 to >3-fold Increased Response Rate for Head and Neck Cancer
Positive Data from Phase Ib Study Evaluating UbiVac’s DPV-001 as Combination Immunotherapy for Head and Neck Squamous Cell Cancer Presented at AACR Meeting PORTLAND, OR, USA, April 6, 2024 /EINPresswire.com/ -- • UbiVac Announces a 2 to >3-fold …